We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

Young Doctors from China Experience IMF's Myeloma Master Class
A group of physicians from leading medical institutions in China came to Los Angeles to learn about myeloma during the International Myeloma Foundation’s recent Myeloma Master Class. In his blog this week, IMF Chairman Dr. Brian Durie, details some of the unique challenges facing these young doctors who, nevertheless, are excited about the future.

IMF Receives Highest 4-Star Charity Rating for 11 Years Running
The IMF has been awarded Charity Navigator’s 4-star, highest rating for 2014! The rating, according to Charity Navigator, indicates that the IMF operates in an ethical and fiscally responsible manner. A 4-star rating is the highest rating a charity can receive from the organization and earning it places the IMF in the “Exceptional” category, meaning the IMF “exceeds industry standards and outperforms most charities in its cause.” Charity Navigator works to promote “a more efficient and responsive philanthropic marketplace, in which givers and the charities they support work in tandem to overcome our nation’s and the world’s most persistent challenges.” We’re proud of our 11-year 4-star rating and honored to serve the myeloma community in finding a cure! Read the detailed rating report, HERE.

FDA Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of MM in Patients Who Have Received One or More Prior Therapies
Bristol-Myers Squibb Company and AbbVie today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies.

Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study
A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the study and a press release issued by daratumumab manufacturers Genmab and Johnson & Johnson, the data showed a 36% response rate in the group treated in phase two of the study and furthermore, 65% of those patients had not experienced disease progression in the 12 months after the start of treatment.

2 Top Medical Journals Weigh in on Potential Danger of Toxic Chemicals
Reports in two highly respected medical journals—the Lancet and the New England Journal of Medicine—agree that weed killers used with genetically modified crops (commonly known as GMOs), such as corn and soybeans, cause cancer. In his blog this week, IMF Chairman Dr. Brian Durie writes that in light of the evidence, it’s vitally important for consumers to know what’s in their food.

ICYMI: Watch the replay of the 2015 Los Angeles Patient & Family Seminar.
Emphasizing education, advocacy and support, the IMF Patient & Family Seminars empower patients and provide invaluable information to the myeloma community. Click here to watch the replay.

Important Update for Myeloma Patients: Selinexor STORM Trials
Selinexor is an orally administered Selective Inhibitor of Nuclear Export, or SINE™, therapy for the treatment of multiple myeloma. Selinexor inhibits the transport of tumor suppressor proteins from the cell nucleus, where they detect cancerous DNA changes and induce cancer cell death. More than 900 patients have been treated with selinexor in phase I and phase II clinical trials and in an ongoing phase I clinical trial, Selinexor in combination with low-dose dexamethasone demonstrated favorable responses. To read more about the Selinexor STORM trials, please click HERE.

Is Precision Medicine What We Need?
In his blog this week, IMF Chariman Dr. Brian Durie compares two opinions on the value of precision medicine as outlined in recent articles in Science and The New England Journal of Medicine. Although precision medicine is popular and ultimately feasible is it the most cost-effective approach to myeloma? he asks. To read Dr. Durie's blog, click HERE.

Proposed "Value Framework" Could Limit Patient Access to Myeloma Drugs
The American Society of Clinical Oncology (ASCO) has created a "Value Framework" in an attempt to balance cancer drug costs with value to the patient. In his blog this week, IMF Chariman Dr. Brian Durie examines the framework's point system. "I believe the proposed system does not work well for myeloma," he writes, "and if implemented could limit needed drug access for myeloma patients." To read Dr. Durie's blog, click HERE.

Can a "Longevity Feast" Be the Key to Longer Life?
In his blog this week, IMF Chairman Dr. Brian Durie discusses a recent New York Times interview with longevity expert Dan Buettner about putting on an Ikarian "Longevity Feast" inspired by his book, The Blue Zones Solution. The book takes a deep dive into five cultures around the world where people have the healthiest and longest lives. While a healthy diet is certainly a cornerstone to vibrant life, Dr. Durie writes that, "spending time with the right mix of friends and family is very important. This natural or organic stress reduction has almost a magical effect." To read the full post, click HERE

    next      view all